Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Respiratory Muscle Training During Breast Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity

Principal Investigator: Levine, Ellis G

A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC) or Hormone Receptor Positive (HR+) Breast Cancer.

Principal Investigator: Kabraji, Sheheryar K

A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Principal Investigator: Hassan, Hamza

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer

Principal Investigator: Dy, Grace K

Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients with Loco-regionally Advanced or Recurrent Colorectal Cancer Undergoing Surgery; Phase I/II

Principal Investigator: Dakwar, Anthony

Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of Decoy20 as Monotherapy and in Combination with Tislelizumab in Patients with Advanced Solid Tumors

Principal Investigator: Krishnamurthy, Anuradha

Thriving Beyond Breast Cancer: Post-Treatment Supportive Services Programming for Breast Cancer Survivors to Optimize Health During Survivorship

Principal Investigator: Devonish, Julia A

A Randomized Double Blinded Trial of Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Principal Investigator: Holtan, Shernan G

Sensory Evaluation of Cigarettes Claiming Removal of Menthol as a Characterizing Flavor

Principal Investigator: O'Connor, Richard J

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination with Standard of Care Treatment in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Principal Investigator: Hillengass, Jens

AFT-65/ASCENT-05 OptimICE-RD: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After…

Principal Investigator: Levine, Ellis G

Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition

Principal Investigator: Chatta, Gurkamal S

(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary

Principal Investigator: Singh, Anurag K

Feasibility of a Community-Based Cancer Survivor Exercise and Nutrition Education Program: Effects on Self Efficacy, Quality of Life and Functional Performance

Principal Investigator: Ray, Andrew D

A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Principal Investigator: Green, Steven D

(AHOD2131) A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Principal Investigator: Kelly, Kara M

A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer ( 27T51-01)

Principal Investigator: Zsiros, Emese

Feasibility Study for ivWatch in prevention of extravasation of vesicants in an oncology setting

Principal Investigator: Storer, Andrew C

A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors

Principal Investigator: Dy, Grace K

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate…

Principal Investigator: Green, Steven D

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1…

Principal Investigator: Wang, Eunice S

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

Principal Investigator: Malek, Ehsan

Investigating The Effect of Testosterone Replacement Therapy Among Hypogonadal Men with Localized Prostate Cancer on Active Surveillance

Principal Investigator: Aly, Ahmed A

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in Patients with Recurrent Ovarian Cancer

Principal Investigator: Zsiros, Emese

2215-CL-0203 A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for…

Principal Investigator: Wang, Eunice S